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Abstract
Objectives Since 2004, uterine fibroids have been treated withMR-HIFU, but there are persevering doubts on long-term efficacy
to date. In the Focused Ultrasound Myoma Outcome Study (FUMOS), we evaluated long-term outcomes after MR-HIFU
therapy, primarily to assess the reintervention rate.
Methods Data was retrospectively collected from 123 patients treated withMR-HIFU at our hospital from 2010 to 2017. Follow-
up duration and baseline (MRI) characteristics were retrieved from medical records. Treatment failures, adverse events, and the
nonperfused volume percentage (NPV%) were determined. Patients received a questionnaire about reinterventions, recovery
time, satisfaction, and pregnancy outcomes. Restrictive treatment protocols were compared with unrestrictive (aiming for
complete ablation) treatments. Subgroups were analyzed based on the achieved NPV < 50 or ≥ 50%.
Results Treatment failures occurred in 12.1% and the number of adverse events was 13.7%. Implementation of an unrestrictive
treatment protocol significantly (p = 0.006) increased the mean NPV% from 37.4% [24.3–53.0] to 57.4% [33.5–76.5]. At 63.5 ±
29.0 months follow-up, the overall reintervention rate was 33.3% (n = 87). All reinterventions were performed within 34 months
follow-up, but within 21 months in the unrestrictive group. The reintervention rate significantly (p = 0.002) decreased from
48.8% in the restrictive group (n = 43; follow-up 87.5 ± 7.3 months) to 18.2% in the unrestrictive group (n = 44; follow-up 40.0 ±
22.1 months). The median recovery time was 2.0 [1.0–7.0] days. Treatment satisfaction rate was 72.4% and 4/11 women
completed family planning after MR-HIFU.
Conclusions The unrestrictive treatment protocol significantly increased the NPV%. Unrestrictive MR-HIFU treatments led to
acceptable reintervention rates comparable to other reimbursed uterine-sparing treatments, and no reinterventions were reported
beyond 21 months follow-up.
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Key Points
• All reinterventions were performed within 34 months follow-up, but in the unrestrictive treatment protocol group, no
reinterventions were reported beyond 21 months follow-up.
• The NPV% was negatively associated with the risk of reintervention; thus, operators should aim for complete ablation during
MR-guided HIFU therapy of uterine fibroids.
• Unrestrictive treatments have led to acceptable reintervention rates after MR-guided HIFU therapy compared to other
reimbursed uterine-sparing treatments.
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Abbreviations
CTCAE Common Terminology Criteria for Adverse
Events
DISC Direct skin cooling
MREC Medical Research Ethics Committee Board
MR-HIFU Magnetic resonance image-guided high-
intensity-focused ultrasound
MRI Magnetic resonance imaging
NPV Nonperfused volume
RFA Radiofrequency ablation
UAE Uterine artery embolization
UMCU University Medical Centre Utrecht
Introduction
Uterine fibroids have a high lifetime prevalence varying be-
tween 70 and 80% [1]. In 25% of women, uterine fibroids
cause clinically significant symptoms. Symptoms can be clas-
sified into three categories: abnormal menstrual bleeding,
bulk-related symptoms, and reproductive dysfunction [2, 3].
To date, hysterectomy is still the most commonly performed
intervention for uterine fibroids. Although effective in reduc-
ing symptoms, hysterectomy is associated with a risk of post-
operative complications and requires several weeks of recov-
ery [4, 5]. Myomectomy is considered the best therapeutic
choice for women desiring pregnancy [6]. Less invasive treat-
ment options are available including uterine artery emboliza-
tion (UAE) and radiofrequency ablation (RFA). Magnetic res-
onance image-guided high-intensity-focused ultrasound (MR-
HIFU) is a completely noninvasive therapy which combines
high-intensity-focused ultrasound for tissue heating with real-
time MRI and MRI-based temperature monitoring for therapy
guidance [7]. A pretreatment MRI is necessary to determine
patient suitability for MR-HIFU [8]. Importantly, not all fi-
broids are suitable for each treatment strategy, but these less
invasive approaches have the obvious advantage of uterine
preservation and allow future childbearing. Other benefits in-
clude less pain posttreatment, less complications, shorter hos-
pital stay, and faster recovery [9, 10]. However, these therapies
have been associated with a higher fibroid recurrence risk. A
systematic review reported a reintervention rate after 3 years
of 7.4% for UAE, 10.4% for RFA, and 34.7% for MR-HIFU
compared to 1.2% for myomectomy [11]. Although that re-
view included MR-HIFU studies using outdated treatment
protocols and older devices, there are persevering doubts on
the long-term efficacy of MR-HIFU. An important predictor
of MR-HIFU treatment success is the ablated fibroid volume
(Fig. 1), e.g., the nonperfused volume (NPV). A higher
NPV% results in greater fibroid shrinkage, improved relief
of symptoms, and lower retreatment rates [12–14].
Technological improvements and treatment protocol modifi-
cations are nowadays leading to increased NPV% [15, 16].
Importantly, data beyond 24 months follow-up of MR-HIFU
treatments with protocols aiming for complete fibroid ablation
is scarce [14].
Objectives
This study was conducted for the evaluation of long-term
outcomes after MR-HIFU therapy of uterine fibroids, primar-
ily to assess the reintervention rate. Secondary outcomes in-
cluded safety, treatment failures, NPV%, treatment satisfac-
tion, and reproductive outcomes.
Materials and methods
Study design
In this retrospective study, women treated with MR-HIFU
from April 2010 to December 2017 at the University
Medical Centre Utrecht (UMCU) in the Netherlands were
included. Data from part of this patient population was used
in previous studies [17–20]. The research protocol (reference
number 17-892) was examined by the Medical Research
Ethics Committee Board (MREC) UMCU and confirmed on
the 18th of January 2018 that the Medical Research Involving
Human Subjects act (WMO) does not apply to our study. Data
was retrospectively retrieved from medical records.
Additional follow-up data was collected using a questionnaire
(see ESM Appendix 1) by mail. All patients signed informed
consent before the initial MR-HIFU treatment and a renewed
informed consent before filling in the questionnaire.
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MR imaging and MR-HIFU treatment
Two radiologists carried out all MR-HIFU procedures,
without prior MR-HIFU experience. The first radiologist
consecutively treated the first 78 patients and the second
radiologist consecutively treated the last 45 patients.
Patients were treated on a clinical MR-HIFU system
(Sonalleve, Profound Medical Inc.) integrated into a 1.5-T
MRI (Achieva, Philips Healthcare) [16]. During the study
period, an upgrade was installed (Sonalleve V1 to V2) in-
cluding a direct skin cooling (DISC) system. Furthermore,
two different MR-HIFU treatment protocols were used.
Therefore, the cohort was subdivided into two subgroups:
restrictive treatment protocol versus unrestrictive treatment
protocol. During the first treatments [18, 19], restrictive
guidelines were followed for safety measures: patient im-
mobilization time was limited to 3 hours, no sensitive struc-
tures (i.e., bone, bowel, scar tissue, clips, bladder with cath-
eter, or nerves) in the near field beam path, far field safety
margin (30 mm) to the spine (or other sensitive structures),
and a cell safety margin (10 mm) from the treatment cell to
the uterine serosa. The unrestrictive treatment protocol allowed
for complete fibroid ablation without time limit or safety mar-
gins (the sonication spot was determined by the operator with
careful assessment of neighboring sensitive structures).
Data collection
Information from medical records was retrieved about (a)
patient characteristics, (b) pretreatment MR parameters, (c)
occurrence of (serious) adverse events; (d) treatment fail-
ures, and (e) NPV% immediately post-MR-HIFU treat-
ment. Follow-up duration was calculated from the initial
MR-HIFU treatment till 04 August 2018. On the pretreat-
ment MRI, the following measurements were performed:
the thickness of the abdominal subcutaneous fat layer, the
number of fibroids, the maximum diameter, and the total
fibroid volume by semiautomatic segmentation in the tumor
tracking function of IntelliSpace Portal (ISP) software
(Philips Healthcare) with review and manual correction of
the segmentation result by an expert. MRI fibroid charac-
teristics consisted of the presence of contrast enhancement
on T1-weighted images and the fibroid’s signal intensity on
the T2-weighted images to determine Funaki classification
[21]. Based on their T2 signal intensity, fibroids can be
classified into three Funaki subtypes (Fig. 2). Funaki types
1 and 2 respond well to MR-HIFU therapy, while treatment
of Funaki type 3 fibroids is not recommended [22].
Treatment failures were defined as treatments canceled
due to bowel interposition, device malfunction, patient dis-
comfort, or inadequate heating of the uterine fibroid. MR-
HIFU treatment failures were not included in further anal-
ysis. Adverse events were identified and graded according
to the Common Terminology Criteria for Adverse Events
(CTCAE) [23]. On the posttreatment MR images, the NPV
was volumetrically measured in ISP and the NPV% was
calculated by the following formula: (NPV/fibroid vol-
ume) × 100%. The need for additional treatment was based
on clinical evaluation. The radiological post-HIFU evalua-
tion was not used to propose additional treatments. Follow-
up data on the need for additional treatment during follow-
up, recovery time in days, patient treatment satisfaction,
and pregnancy outcomes were collected using a question-
naire. A reintervention was defined as second MR-HIFU
treatment, embolization, myomectomy, or hysterectomy.
The continued use of medication was not considered a
reintervention. Repeat MR-HIFU treatments for other fi-
broids or large fibroids scheduled in two tempi were not
considered reinterventions. A subanalysis for the
reintervention rate was performed based on the achieved
NPV < 50 or ≥ 50%, and this cutoff point is in concordance
with previous publications [12, 17, 24, 25]. Until 2013, a
wish for future pregnancy was an exclusion criterion.
Despite this, all patients were asked if they had a desire
for future pregnancy prior to the MR-HIFU treatment and
whether they conceived during follow-up.
Fig. 1 Pretreatment and posttreatment images: a T2-weighted image from the screening MRI, (b) gadolinium-enhanced T1-weighted image from the
screening MRI, and (c) the same sequence immediately post-MR-HIFU treatment
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Statistics
For statistical analysis, IBM SPSS Statistics 25 was used.
The level of statistical significance was set at p < 0.05. A
Mann–Whitney U test was used to calculate significant
difference of NPV% between treatment protocols and
reintervention groups and to compare follow-up duration
between subgroups. Chi-square test was used to calculate
s ignif icant difference of treatment fai lures and
reintervention rate between Funaki types, treatment proto-
cols, and NPV subgroups. A Cox regression was used to
evaluate the relat ionship between undergoing a
reintervention (outcome) and the NPV% achieved imme-
diately after treatment (predictor) as well as the relation-
ship between a reintervention and the treatment protocol
used. Cox regression was performed and corrected for any
possible confounding effects such as NPV% and treat-
ment protocol. The probabil i ty of undergoing a
reintervention as a function of time was analyzed by a
Kaplan–Meier curve. The NPV% was compared between
patients lost to follow-up and patients who completed the
follow-up. We stratified outcomes by system (V1/V2),
treating radiologist, treatment protocol, NPV%, follow-
up duration, and Funaki type.
Results
One hundred and twenty-three patients were treated with
MR-HIFU between April 2010 and December 2017. The
flowchart of the selection process is shown in Fig. 3.
Eleven patients were excluded from the analysis. A total
of 124 MR-HIFU treatments were performed on 112 pa-
tients. Twelve patients were treated in two tempi due to
(a) treatment volume of the fibroid which was not treat-
able in a single session, (b) the treatment of multiple fi-
broids, and (c) the occurrence of technical failure during
the first treatment.
Procedure-related outcomes
Overall, 17 adverse events occurred (13.7%) in 124 treat-
ments. The reported adverse events were skin redness, first-
and second-degree skin burns, abdominal pain, malaise, vag-
inal discharge or bleeding, hematuria, cystitis, and
neuropraxia (Table 1). Only mild (grade 1; n = 13) and mod-
erate (grade 2; n = 4) adverse events were reported.
Stratification by system, treatment protocol, or treating radiol-
ogist showed no significant differences in the total number of
Fig. 3 Flowchart of participants
Fig. 2 Funaki classification: a Funaki I fibroid (signal intensity lower than myometrium and muscle), (b) Funaki II fibroid (signal intensity lower than
myometrium, but higher than muscle), and (c) Funaki III fibroid (signal intensity higher than muscle and myometrium)
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adverse events. However, all skin burns were reported in treat-
ments performed with the V1.
Treatment failures occurred in 12.1% (15/124) of the MR-
HIFU treatments (Table 1). Four patients underwent a second
MR-HIFU treatment. The other patients (n = 11) chose not to
undergo a second MR-HIFU treatment and were excluded
from further analysis. Stratification by system or treating ra-
diologist showed no significant differences in treatment
failures.
The mean NPV%of the remaining 101 patients was 48.4 ±
25.0% (2.1–100.0). The median NPV% was significantly dif-
ferent between the restrictive (37.4% [24.3–53.0], n = 47) and
unrestrictive (57.4% [33.5–76.5], n = 54) treatment protocol,
p = 0.006. The median NPV% of the patients that returned the
questionnaire was lower (41.0 [28.3–66.1], n = 87) compared
to the patients who did not return the questionnaire (65.3
[38.3–77.7], n = 14).
Clinical outcomes
In total, 87/101 patients returned the questionnaires (Fig. 3).
Baseline characteristics are shown in Table 2. The mean
follow-up duration was 63.5 ± 29.0 months (range 8–
100 months).
Twenty-nine of the 87 patients (33.3%) required additional
treatment during the follow-up period due to fibroid-related
symptoms (Table 3), consisting of 6 second MR-HIFU thera-
pies (21%), 4 UAE (14%), 2 myomectomies (7%), and 17
hysterectomies (58%).
Longer follow-up was associated with a higher risk for a
reintervention (Fig. 4). All reinterventions were performed
within 34 months of the initial MR-HIFU treatment.
We found a significant difference (p = 0.012) in NPV%
between patients who underwent a reintervention (n = 29)
and patients with no reintervention (n = 58) with a median
NPV% of 35.7% [26.9–44.9] and 49.7% [30.2–73.3],
respectively. Furthermore, NPV% was negatively associated
with the risk of reintervention (HR 0.977 (95% CI 0.961–
0.994), p = 0.009). Analysis showed no confounding effect
of treatment protocol regarding NPV% prediction of
outcome.
Comparison of the two treatment protocols (p = 0.002)
showed that more patients treated with the restrictive protocol
(21/43) needed additional treatment than patients treated with
the unrestrictive protocol (8/44)—48.8 versus 18.2%
(Table 3). Cox regression confirmed this: the unrestrictive
treatment protocol lowers the risk of reintervention (HR
0.275 (95% CI 0.111–0.681), p = 0.005). The follow-up of
the patients treated with an unrestricted protocol was also
shorter (40.0 ± 22.1 vs. 87.5 ± 7.3 months, p < 0.001)
However, no reintervention was reported in this subgroup be-
yond 21 months follow-up.
A subanalysis was performed based on the achieved
NPV%. In 36 of the 87 patients (41.4%), a NPV ≥ 50% was
achieved. The reintervention percentage of these 36 patients
was 16.7% (6/36), whereas 23 patients out of 51 patients with
a NPV< 50% (45.1%; p = 0.021) required additional interven-
tion during follow-up (Table 3). The mean follow-up duration
was not significantly different for these two groups (p =
0.281)—58.7 ± 30.2 (9–99) months and 66.8 ± 28.0 (8–100)
months, respectively.
Stratification of the Funaki types led to a reintervention rate
of 100% in Funaki type 3 fibroids (2/2), 39.3% for type 2 (24/
61), and 12.5% for type 1 (3/24). The reintervention rate be-
tween Funaki 2 and Funaki 3 fibroids was not significantly
different (p = 0.086), but was significant between Funaki 1
and Funaki 2 fibroids (p = 0.017). Funaki 3 fibroid treatments
had a failure rate of 60% (6/10), compared to 10.7% (8/75) for
Funaki 2 and 3.7% (1/27) for Funaki 1 fibroids. This treatment
failure rate was significantly different for Funaki 2 and 3 fi-
broids (p = 0.001), but not for Funaki 1 and 2 fibroids
(p = 0.274).
Table 1 Specification of adverse events (n = 17) during 124 treatments on the left and specification of causes of treatment failure (n = 15) on the right
Adverse events n (%) Treatment failures n (%)
Total 17 (13.7) Total 15 (12.1)
Skin redness 3 (2.4) Inadequate heating 4 (3.2)
Skin burnsa 4 (3.2) Treatment of a Funaki 3 fibroid 3 (2.4)
Cystitis 1 (0.8) Physical discomfort, movement, and/or pain 3 (2.4)
Abdominal painb 3 (2.4) Interposition of intestine 2 (1.6)
Malaise 1 (0.8) Failure of the technology 2 (1.6)
Vaginal discharge or bleedingb 3 (2.4) Vasovagal episode during treatment 1 (0.8)
Hematuria 1 (0.8)
Neuropraxiac 2 (1.6)
a Only first- and second-degree skin burns were reported
bOne woman reported abdominal and pain vaginal bleeding
c Neuropraxia of L5 (caused by nontarget heating) and neuropraxia of the brachial plexus (due to positioning difficulties in the bore) were reported
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The median recovery time before patients returned to work
or their normal activities was 2.0 [1.0–7.0] (0–60) days.
Fifty-eight out of 87 patients (66.7%) reported about their
treatment satisfaction. The other 29 (33.3%) had difficulties
remembering because too much time had passed since the
treatment. Of those 58 patients, 42 patients (72.4%) were sat-
isfied with the treatment procedure at the hospital and 51/58
patients (87.9%) would recommend this treatment to other
women.
In total, 63 patients answered the questions regarding preg-
nancy of which 11 still had a desire for future pregnancy when
they underwent MR-HIFU therapy. Four women (36.4%)
conceived, resulting in nine pregnancies two of which resulted
in early pregnancy losses and seven in livebirths (six at term
and one preterm). Mode of delivery was a Cesarean section in
three cases and two vaginal deliveries. Reported complica-
tions during pregnancy were fibroid’s necrosis, obstruction
of labor (n = 1), and postpartum hemorrhage (n = 2).
Discussion
To the best of our knowledge, this retrospective study has the
longest follow-up after MR-HIFU treatment of uterine fi-
broids reported to date. Previous publications all had a
follow-up of 2 years or shorter [26, 27]. Only Mohr-Sasson
et al had an average follow-up of 36.5 months [28]. Our mean
follow-up of 63.5 months exceeds that study.
Similar to our study, longer follow-up is associated with a
higher risk for a reintervention [29, 30]. However, all
reinterventions were performed within 34 months follow-up
and no reinterventions were reported beyond 21 months
follow-up in the unrestrictive treatment protocol group.
Although this might be partially explained by women becom-
ing postmenopausal, it is an important finding for future study
designs.
Our reintervention rate after MR-HIFU was 33.3%, which
is relatively high, but our studies included treatment with both
restricted and unrestricted protocols, and it can be expected
that the reintervention rate in this study is higher than studies
only including treatment protocols aiming for full ablation, as
illustrated by our nonrestrictive treatments which decreased
the reintervention rate to 18.2%.
The probability of requiring reintervention decreases as the
NPV% increases [13]. Our reintervention rate was lower when
the achieved NPV% was ≥ 50% (16.7 vs. 45.1%), and imple-
mentation of an unrestricted treatment protocol led to a higher
Table 3 Clinical outcomes at the end of follow-up
Follow-up outcomes*
Duration of follow-up (months) (n = 87) 63.5 ± 29.0 (8–100)
74.0 [37.0–88.0]
Recovery time (days) (n = 87) 5.8 ± 9.7 (0–60)
2.0 [1.0–7.0]
Treatment satisfaction rate (n = 58/87)
Satisfied 42/58 (72.4)
Unsatisfied 16/58 (28.6)
Reinterventions 29/87 (33.3)
Hysterectomy 17/29 (58.0)
Myomectomy 2/29 (7.0)
Uterine artery embolization 4/29 (14.0)
Repeat MR-HIFU 6/29 (21.0)
Reintervention subgroup analysis
Restrictive protocol group (n = 43)a 21/43 (48.8)
Unrestrictive protocol group (n = 44)a 8/44 (18.2)
NPVb < 50% (n = 51)c 23/51 (45.1)
NPVb ≥ 50% (n = 36)c 6/36 (16.7)
Funaki 1 (n = 24) 3/24 (12.5)
Funaki 2 (n = 61) 24/61 (39.3)
Funaki 3 (n = 2) 2/2 (100)
*Data presented as n, n (%), or mean ± SD (range) and median [Q1–Q3]
a The follow-up of patients treated with an unrestricted protocol was sig-
nificantly shorter—40.0 ± 22.1 versus 87.5 ± 7.3 months (median 41.0
[18.3–62.0] vs. 88.0 [82.0–94.0] months)
b Nonperfused volume percentage
c The follow-up between the NPV subgroups was not significantly differ-
ent—58.7 ± 30.2 versus 66.8 ± 28.0 months (median 62.5 [29.5–89.8] vs.
79.0 [47.0–87.0] months
Table 2 Baseline characteristics of all patients (n = 87)
Baseline characteristics*
Number of patients 87
Age (years) 44.6 ± 4.7 (30.8–54.1)
44.5 [41.2–48.2]
Duration of follow-up (months) 63.5 ± 29.0 (8–100)
74.0 [37.0–88.0]
Number of fibroids
1 39 (44.8)
2 13 (14.9)
3 8 (9.2)
4 10 (11.5)
≥ 5 17 (19.5)
Targeted fibroid diameter (cm) 9.3 ± 3.1 (3–18.9)
9.1 [7.0–11.5]
Targeted fibroid volume (cm3) 347.3 ± 260.8 (7.4–1490.3)
305.0 [158.0–505.2]
Targeted fibroid Funaki intensity
1 24 (27.6)
2 61 (70.1)
3 2 (2.3)
Subcutaneous fat layer (cm) 1.2 ± 0.6 (0.1–3.1)
1.0 [0.8–1.6]
*Data presented as n, n (%), or mean ± SD (range) and median [Q1–Q3]
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mean NPV% [16]. Therefore, operators nowadays should aim
for complete ablation to reduce the reintervention risk.
As outlined above, none of the earlier MR-HIFU studies
had a comparable follow-up duration, but 5-year outcomes
after ultrasound-guided HIFU treatments have been reported
previously. Sandberg et al compared long-term reintervention
rates after several uterine-sparing treatments of uterine fi-
broids [11]. At 60 months, the reintervention rate was 12.2%
for myomectomy, 14.4% for UAE, and 53.9% after MR-
HIFU which is higher than our reintervention rate of 33.3%.
Two studies compared MR-HIFU to UAE [17, 31], and
they reported lower reintervention rates and greater improve-
ment in symptoms after UAE. However, the mean NPV% in
both trials was below 50% [32]. More recent studies reported
lower retreatment rates: 12.7% afterMR-HIFU at 19.4months
(comparable to UAE) [13, 28]. The latter study compared
long-term outcomes of MR-HIFU to laparoscopic myomecto-
my and found no significant differences in symptom reduc-
tion, quality of life, or reintervention rates.
Importantly, the average recovery time after MR-HIFU in
our study was 5.8 ± 9.7 days, compared to 22.1 ± 12.3 days for
myomectomy and 11.9 ± 5.9 days for UAE [33]. This implies
both reduced hospital stay as absenteeism, which decreases
both the economic and social burden of uterine fibroids.
Further large controlled trials, comparing the presently avail-
able different treatments for uterine fibroids and utilizing the
newest equipment and treatment protocols, are needed to con-
firm these findings.
The number of patients desiring pregnancy in this study
was too small to determine the pregnancy rate, because a
desire for future childbearing was an exclusion criterion until
2013 [18]. However, similar to previous cohort studies, the
pregnancy outcomes after MR-HIFU treatment in this study
were reassuring [34], contrary to UAE, which can compro-
mise ovarian reserve, and thereby fertility, as suggested by the
significantly decrease in anti-Mullerian hormone levels com-
pared to HIFU in the FIRSTT study [31]. Moreover, MR-
HIFU also has the benefit of no waiting period before
attempting to conceive. Therefore, MR-HIFU might be a
promising treatment for women desiring pregnancy, but the
effect of MR-HIFU on fertility should be examined in more
detail.
Our study demonstrated that MR-HIFU treatment was safe
because the number of adverse events was acceptable.
However, the treatment failure rate in this study was relatively
high (12.1%). This could be partially explained by two learn-
ing curves of both radiologists without prior MR-HIFU abla-
tion experience [35]. Additionally, bowel-interference mitiga-
tion techniques were not implemented, which may have re-
sulted in more treatment failures or low NPV% due to inter-
position of small bowel loops at the day of the MR-HIFU
treatment [36]. Furthermore, none of the patients with
Funaki type 3 fibroids had successful MR-HIFU treatment,
underlining that these fibroids are difficult to treat and that
better fibroid selection could further decrease the
reintervention rate [22].
Limitations of this study were related to the design of a
nonrandomized, retrospective cohort study. Recall bias is a
limitation as with all survey studies. In addition, the risk at a
selection bias was high, because treatment choice was based
on patient’s preference. Furthermore, two learning curves of
the treating radiologists may have complicated the evaluation
of our treatment results, but we expected that the treatment
protocol subgroups were equally influenced because the sec-
ond learning curve started during the unrestrictive treatments.
Additionally, the treatment of Funaki type 3 fibroids affected
our reintervention analyses. Another study limitation is the
difference in follow-up duration between the treatment proto-
cols. Moreover, the mean NPV% was below 50% which is
lower than achieved in more recently published studies [13,
Fig. 4 Probability of undergoing
reintervention over time
(months), stratified by treatment
protocol showing a significant
difference (p = 0.005)
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28, 37]. This can be explained by operator experience, restric-
tive treatment guidelines, and technological improvements.
For example, the greater maximum depth of the Sonalleve
V2 and the reduced cooling times with DISC both result in
larger NPV% (and subsequently lower reintervention rates).
Lastly, the assessment of NPV% was done immediately fol-
lowing MR-HIFU when apoptosis effects have not been com-
pleted yet [38–40]. Therefore, the NPV% is systematically
underestimated.
Specific patient groups may benefit from MR-HIFU such
as women with a desire to conceive or as a bridge to meno-
pause in older women. The best treatment option for uterine
fibroids is influenced by a woman’s symptoms, age, pregnan-
cy wish, fibroid location, and patient’s preference [41].
Besides, final therapy is also influenced by fibroid character-
istics since not all fibroids are suitable for each treatment strat-
egy. This illustrates the importance of personalized healthcare
for women with uterine fibroids.
Conclusion
The mean follow-up duration was 63.5 months, but all
reinterventions were performed within 34 months.
Importantly, no reinterventions were reported beyond
21 months in the unrestrictive treatment protocol group. The
NPV% was negatively associated with the risk of
reintervention; thus, operators should aim for complete fibroid
ablation. Unrestrictive MR-HIFU treatments have led to ac-
ceptable reintervention rates compared to other reimbursed
uterine-sparing treatments.
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tion for treatment of symptomatic uterine fibroids: comparison of symp-
tom improvement and reintervention rates. Eur Radiol 24:2649–2657.
https://doi.org/10.1007/s00330-014-3295-6
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Eur Radiol 23:3054–61. https://doi.org/10.1007/s00330-013-2915-x
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1007/s00330-011-2262-8
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guided high-intensity focused ultrasound with direct skin cooling for the
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Methodology
• Retrospective
• Case–control study
• Performed at one institution
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